Oncogenic PKC- activates Vimentin during epithelial-mesenchymal transition in melanoma; a study based on PKC- and PKC- specific inhibitors

Melanoma is one of the fastest growing cancers in the United States and is accompanied with a poor prognosis owing to tumors being resistant to most therapies. Atypical protein kinase Cs (aPKC) are involved in malignancy in many cancers. We previously reported that aPKCs play a key role in melanoma's cell motility by regulating cell signaling pathways which induce epithelial-mesenchymal Transition (EMT). We tested three novel inhibitors; [4-(5-amino-4-carbamoylimidazol-1-yl)-2,3-dihydroxycyclopentyl] methyl dihydrogen phosphate (ICA-1T) along with its nucleoside analog 5-amino-1-((1R,2S,3S,4R)-2,3-dihydroxy-4-methylcyclopentyl)-1H-imidazole-4-carboxamide (ICA-1S) which are specific to protein kinase C-iota (PKC-) and 8-hydroxy-1,3,6-naphthalenetrisulfonic acid (-Stat) which is specific to PKC-zeta (PKC-) on cell proliferation, apoptosis, migration and invasion of two malignant melanoma cell lines compared to normal melanocytes. Molecular modeling was used to identify potential binding sites for the inhibitors and to predict selectivity. Kinase assay showed >50% inhibition for specified targets beyond 5M for all inhibitors. Both ICA-1 and -Stat significantly reduced cell proliferation and induced apoptosis, while ICA-1 also significantly reduced migration and melanoma cell invasion. PKC- stimulated EMT via TGF/Par6/RhoA pathway and activated Vimentin by phosphorylation at S39. Both ICA-1 and -Stat downregulate TNF- induced NF-B translocation to the nucleus there by inducing apoptosis. Results suggest that PKC- is involved in melanoma malignancy than PKC-. Inhibitors proved to be effective under in-vitro conditions and need to be tested in-vivo for the validity as effective therapeutics. Overall, results show that aPKCs are essential for melanoma progression and metastasis and that they could be used as effective therapeutic targets for malignant melanoma.